The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
Open accessAbstract
Purpose: The aim of this study was to analyze chromosomal aberrations in terms of frequency and impact on time to progression in patients with smoldering multiple myeloma (SMM) on the background of clinical prognostic factors. Patients and Methods: The chromosomal abnormalities 1q21, 5p15/5q35, 9q34, 13q14.3, 15q22, 17p13, t(11;14)(q13;q32), and t(4;14)(p16.3;q32) were assessed in CD138-purified myeloma cells by interphase fluorescent in situ hybridization (iFISH) alongside clinical parameters in a consecutive series of 248 patients with SMM. Results: The high-risk aberrations in active myeloma (ie, del(17p13), t(4;14), and +1q21) present in 6.1%, 8.9%, and 29.8% of patients significantly confer adverse prognosis in SMM with hazard ratios (HRs) of 2.90 (95% CI, 1.56 to 5.40), 2.28 (95% CI, 1.33 to 3.91), and 1.66 (95% CI, 1.08 to 2.54), respectively. Contrary to the conditions in active myeloma, hyperdiploidy, present in 43.3% of patients, is an adverse prognostic factor (HR, 1.67; 95% CI, 1.10 to 2.54). Percentage of malignant bone marrow plasma cells assessed by iFISH and combination of M-protein and plasma cell infiltration as surrogates of tumor load significantly confer adverse prognosis with HRs of 4.37 (95% CI, 2.79 to 6.85) and 4.27 (95% CI, 2.77 to 6.56), respectively. In multivariate analysis, high-risk aberrations, hyperdiploidy, and surrogates of tumor load are independently prognostic. Conclusion: The high-risk chromosomal aberrations del(17p13), t(4;14), and +1q21 are adverse prognostic factors in SMM just as they are in active myeloma, independent of tumor mass. Hyperdiploidy is the first example for an adverse prognostic factor in SMM of opposite predictiveness in active myeloma. Risk association of chromosomal aberrations is not only a priori treatment dependent (predictive) but is also an intrinsic property of myeloma cells (prognostic).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with t(4;14) translocation, del(17p), and gain(1q) are at a higher risk of progression from MGUS or SMM to multiple myeloma.21–23”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,309
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 940
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Bladé, J., Merlini, G., Kröger, N. M., Einsele, H., Vesole, D. H., Dimopoulos, M. A., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 886
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–233 of 233
Ossäre Manifestationen des multiplen Myeloms
Goldschmidt, H., Hose, D., & Hillengaß, J. (2014) · Springer eBooks · doi:10.1007/978-3-662-43471-0_15
Self-citationMicrofluidics-based Single Cell Analytical Platforms for Characterization of Cancer
Kristoffersen, E. L., Jepsen, M. L., Knudsen, B. R., & Ho, Y. (2016) · Advances in delivery science and technology · doi:10.1007/978-1-4939-3634-2_5
R-ISS and NLR-ISS can Predict Time to Treatment in Smoldering Myeloma
Romano, A., Consoli, M. L., & Auteri, G. (2016) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000292
The Value of Anti-angiogenics in Multiple Myeloma Therapy
Moehler, T. M., Hose, D., Andrulis, M., Seckinger, A., & Goldschmidt, H. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_34
Self-citationSmoldering (asymptomatic) Multiple Myeloma: Cure-versus-control Debate
Hamed, N. A. M. (2015) · doi:10.24947/baojcrt/1/2/00110
Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group
Mateos, M., Bladé, J., Lahuerta, J. J., & Miguel, J. F. S. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.05.003
Multiple Myeloma and Other Plasma Cell Neoplasms
Lin, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-20279-2_13
ElGhammaz, A. (2016) · Egyptian Journal of Hematology and Bone Marrow Transplantation · doi:10.21608/ejhbmt.2016.19697
Therapeutic Targets and Signaling Pathways for Diagnosis of Myeloma
Ahmed, Z. A., Nasir, A., Shaikh, M. S., Moatter, T., & Rasheed, A. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81751
The Value of Anti-Angiogenics in Multiple Myeloma Therapy
Moehler, T. M., Hose, D., Andrulis, M., Seckinger, A., & Goldschmidt, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-31215-6_34-1
Self-citationSchulz, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-21215-4.00014-7
Mateos, M., & Miguel, J. F. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_26
E28 Literaturhinweise und Internetadressen
(2015) · Elsevier eBooks · doi:10.1016/b978-3-437-21213-0.16001-2
Schulz, C. (2017) · Elsevier eBooks · doi:10.1016/b978-3-437-21214-7.00014-6
Evaluación de estrategias inmunes para el control del mieloma múltiple a largo plazo
Valls, J. D. (2022) · Gredos (University of Salamanca) · doi:10.14201/gredos.150753
An unusual presentation of paraproteinemia: Call for a new entity
Chauhan, K., Kathuria, K., & Hatwal, V. (2023) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_162_22
EXABS-121-MM MGUS/SMM: Incidence, Evaluation and Follow-up
Schmidt, T. M., & Callander, N. S. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(23)00292-6
Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma
Boquoi, A. (2023) · Journal of Blood Disorders · doi:10.26420/jblooddisordl.2023.1082
Introduction to Multiple Myeloma and Multiple Myeloma Bone Disease
Esteghamat, N., & Abedi, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-52001-3_10
Related Research and Progress of Radiomics in Multiple Myeloma
张, 楠. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551438
Multiple Myeloma and Other Plasma Cell Neoplasms
Lin, P. Y., & Linden, M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10940-9.00022-8
Three-Dimensional Organization of Telomeres: An Emerging Prognostic Biomarker in Multiple Myeloma
Shifrin, Y., & Mai, S. (2025) · Cells · doi:10.3390/cells14231890
Uehara, A., Narita, K., Fujii, F., Sakuma, H., Oura, M., Toho, M., Ikeda, D., Tabata, R., Takeuchi, M., & Matsue, K. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04117-7
Navigating the evolving management of smoldering multiple myeloma
Hammami, M. B., Canevarolo, R. R., Silva, A. S., Alsina, M., Kumar, N. B., Baz, R., & Shain, K. H. (2026) · HemaSphere · doi:10.1002/hem3.70275
The genetic architecture of plasma cell disorders
Boyle, E. M. (2020) · theses.fr (ABES) · doi:10.70675/404c872dz0ef2z4f8eza81fz592360ed443b
Arora, K., Soueid, L., Williams, L., Grover, J., Basali, D., Khouri, J., Kaushal, Y., Mazzoni, S., Dahiya, R., Faiman, B. M., et al. (2026) · Cancers · doi:10.3390/cancers18101505
Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 3
Gonzales, M., Santos, J., Cruz, A., & Reyes, C. (2025) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/fufzqlzvun
Metadata
- Authors
- Neben, K., Jauch, A., Hielscher, T., Hillengass, J., Lehners, N., Seckinger, A., Granzow, M., Raab, M. S., Ho, A. D., Goldschmidt, H., & Hose, D.
- Affiliations
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2013-12-01
- Volume
- 31
- Issue
- 34
- Pages
- 4325-4332
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2126894260
- Semantic Scholar
- 3454ef568a1d73e48a414842f0c56b0cc223ddf6
- Cited by
- 233
- References
- 32
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 17 · 2023: 16 · 2022: 13 · 2021: 24 · 2020: 23 · 2019: 13 · 2018: 20 · 2017: 21 · 2016: 18 · 2015: 26 · 2014: 25 · 2013: 2
- FWCI
- 16.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB TRR 79)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- smoldering multiple myeloma, progression to multiple myeloma, chromosomal abnormalities, 17p deletion, hyperdiploidy, tumor burden, prognostic factors, time to progression, M protein, plasma cell infiltration
- MeSH terms
- Chromosome Deletion, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 17, Chromosomes, Human, Pair 4, Humans, Multiple Myeloma, Phenotype, Ploidies, Risk Factors, Translocation, Genetic, Multivariate Analysis, Proportional Hazards Models, In Situ Hybridization, Fluorescence, Disease Progression, Genetic Predisposition to Disease, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
